Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study
Pancreatic adenosquamous carcinoma (PASC) account for
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2023-05, Vol.152 (9), p.1894-1902 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1902 |
|---|---|
| container_issue | 9 |
| container_start_page | 1894 |
| container_title | International journal of cancer |
| container_volume | 152 |
| creator | Auvray Kuentz, Marie Hautefeuille, Vincent Mestier, Louis Coutzac, Clélia Lecomte, Thierry Nardon, Victor Artru, Pascal Turpin, Anthony Drouillard, Antoine Malka, David Tran‐Minh, My‐Linh Trouilloud, Isabelle Lièvre, Astrid Williet, Nicolas Pernot, Simon Touchefeu, Yann Taieb, Julien Hammel, Pascal Zaanan, Aziz |
| description | Pancreatic adenosquamous carcinoma (PASC) account for |
| doi_str_mv | 10.1002/ijc.34414 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03969427v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2782989314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3824-b223cc7524d5a1a1863c0ff1359c4f997bea5c316096423aea45d8ed3d6c10da3</originalsourceid><addsrcrecordid>eNp1kUlrHDEQhUVIiCdODvkDQZCLc2hbpaW7ldsweGXAl-QsNFI1o6E3S90T5t9HzniBgE8FVR-v6tUj5Cuwc2CMX4SdOxdSgnxHFsB0VTAO6j1Z5BkrKhDlCfmU0o4xAMXkR3IiSlVyAWxB3GqL3TBtMdrxQENPrd_b3qGnYy4R7RRc7mE_pIfZdsOcqLPRhX7o7E-6pBGnOKQR3RT2SLu5zTz2E0a6vL68p2ma_eEz-dDYNuGXp3pKfl9d_lrdFOv769vVcl04UXNZbDgXzlWKS68sWKhL4VjTgFDayUbraoNWOQEl06XkwqKVytfohS8dMG_FKflx1N3a1owxdDYezGCDuVmuzWOPCV1qyas9ZPbsyI5xeJgxTaYLyWHb2h6zScMrVQOw_K6Mfv8P3Q1z7LOTTNVc11qAfF3u8j9SxOblAmDmMSWTUzL_UsrstyfFedOhfyGfY8nAxRH4E1o8vK1kbu9WR8m_vZCanA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2782989314</pqid></control><display><type>article</type><title>Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Auvray Kuentz, Marie ; Hautefeuille, Vincent ; Mestier, Louis ; Coutzac, Clélia ; Lecomte, Thierry ; Nardon, Victor ; Artru, Pascal ; Turpin, Anthony ; Drouillard, Antoine ; Malka, David ; Tran‐Minh, My‐Linh ; Trouilloud, Isabelle ; Lièvre, Astrid ; Williet, Nicolas ; Pernot, Simon ; Touchefeu, Yann ; Taieb, Julien ; Hammel, Pascal ; Zaanan, Aziz</creator><creatorcontrib>Auvray Kuentz, Marie ; Hautefeuille, Vincent ; Mestier, Louis ; Coutzac, Clélia ; Lecomte, Thierry ; Nardon, Victor ; Artru, Pascal ; Turpin, Anthony ; Drouillard, Antoine ; Malka, David ; Tran‐Minh, My‐Linh ; Trouilloud, Isabelle ; Lièvre, Astrid ; Williet, Nicolas ; Pernot, Simon ; Touchefeu, Yann ; Taieb, Julien ; Hammel, Pascal ; Zaanan, Aziz</creatorcontrib><description>Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression‐free survival (PFS) were evaluated by Kaplan‐Meier method. Ninety‐four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first‐line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine‐nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P = .67) or OS (P = .5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P = .002), PFS (median, 7.8 vs 4.7 months, P = .02) and OS (median, 12.7 vs 9.2 months, P = .35). This large study evaluating first‐line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
What's new?
Pancreatic adenosquamous carcinoma (PASC) is a rare pancreatic cancer subtype of uncertain histological origin. Owing to its scarcity, little is known about the efficacy of chemotherapy for PASC, particularly for advanced disease. Here, investigation of modern chemotherapy regimens in a large multicenter cohort consisting of patients with advanced PASC suggests that more recent regimens based on 5‐fluorouracil, particularly FOLFIRINOX (FX), as well as regimens based on gemcitabine, namely gemcitabine‐nab paclitaxel (GN), are more effective for advanced PASC compared to more conventional regimens. Notably, overall response rates and survival rates were improved in advanced PASC patients on FX and GN regimens.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.34414</identifier><identifier>PMID: 36562310</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma ; Adenosquamous ; adenosquamous carcinoma ; advanced disease ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer ; Carcinoma, Adenosquamous - chemically induced ; Carcinoma, Adenosquamous - drug therapy ; Chemotherapy ; Deoxycytidine ; Fluorouracil - therapeutic use ; Gemcitabine ; Humans ; Leucovorin - therapeutic use ; Life Sciences ; Male ; Malignancy ; Medical research ; Metastases ; Paclitaxel ; Paclitaxel - therapeutic use ; Pancreas ; Pancreatic cancer ; Pancreatic carcinoma ; Pancreatic Neoplasms ; Pancreatic Neoplasms - pathology ; Prospective Studies ; Retrospective Studies ; Squamous cell carcinoma ; Survival</subject><ispartof>International journal of cancer, 2023-05, Vol.152 (9), p.1894-1902</ispartof><rights>2022 UICC.</rights><rights>2023 UICC</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3824-b223cc7524d5a1a1863c0ff1359c4f997bea5c316096423aea45d8ed3d6c10da3</cites><orcidid>0000-0002-1258-861X ; 0000-0002-7296-5464 ; 0000-0001-8372-5653 ; 0000-0001-5093-0212 ; 0000-0002-7948-1331</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.34414$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.34414$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36562310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03969427$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Auvray Kuentz, Marie</creatorcontrib><creatorcontrib>Hautefeuille, Vincent</creatorcontrib><creatorcontrib>Mestier, Louis</creatorcontrib><creatorcontrib>Coutzac, Clélia</creatorcontrib><creatorcontrib>Lecomte, Thierry</creatorcontrib><creatorcontrib>Nardon, Victor</creatorcontrib><creatorcontrib>Artru, Pascal</creatorcontrib><creatorcontrib>Turpin, Anthony</creatorcontrib><creatorcontrib>Drouillard, Antoine</creatorcontrib><creatorcontrib>Malka, David</creatorcontrib><creatorcontrib>Tran‐Minh, My‐Linh</creatorcontrib><creatorcontrib>Trouilloud, Isabelle</creatorcontrib><creatorcontrib>Lièvre, Astrid</creatorcontrib><creatorcontrib>Williet, Nicolas</creatorcontrib><creatorcontrib>Pernot, Simon</creatorcontrib><creatorcontrib>Touchefeu, Yann</creatorcontrib><creatorcontrib>Taieb, Julien</creatorcontrib><creatorcontrib>Hammel, Pascal</creatorcontrib><creatorcontrib>Zaanan, Aziz</creatorcontrib><title>Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression‐free survival (PFS) were evaluated by Kaplan‐Meier method. Ninety‐four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first‐line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine‐nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P = .67) or OS (P = .5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P = .002), PFS (median, 7.8 vs 4.7 months, P = .02) and OS (median, 12.7 vs 9.2 months, P = .35). This large study evaluating first‐line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
What's new?
Pancreatic adenosquamous carcinoma (PASC) is a rare pancreatic cancer subtype of uncertain histological origin. Owing to its scarcity, little is known about the efficacy of chemotherapy for PASC, particularly for advanced disease. Here, investigation of modern chemotherapy regimens in a large multicenter cohort consisting of patients with advanced PASC suggests that more recent regimens based on 5‐fluorouracil, particularly FOLFIRINOX (FX), as well as regimens based on gemcitabine, namely gemcitabine‐nab paclitaxel (GN), are more effective for advanced PASC compared to more conventional regimens. Notably, overall response rates and survival rates were improved in advanced PASC patients on FX and GN regimens.</description><subject>Adenocarcinoma</subject><subject>Adenosquamous</subject><subject>adenosquamous carcinoma</subject><subject>advanced disease</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer</subject><subject>Carcinoma, Adenosquamous - chemically induced</subject><subject>Carcinoma, Adenosquamous - drug therapy</subject><subject>Chemotherapy</subject><subject>Deoxycytidine</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Leucovorin - therapeutic use</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Malignancy</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Paclitaxel</subject><subject>Paclitaxel - therapeutic use</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic carcinoma</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Squamous cell carcinoma</subject><subject>Survival</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUlrHDEQhUVIiCdODvkDQZCLc2hbpaW7ldsweGXAl-QsNFI1o6E3S90T5t9HzniBgE8FVR-v6tUj5Cuwc2CMX4SdOxdSgnxHFsB0VTAO6j1Z5BkrKhDlCfmU0o4xAMXkR3IiSlVyAWxB3GqL3TBtMdrxQENPrd_b3qGnYy4R7RRc7mE_pIfZdsOcqLPRhX7o7E-6pBGnOKQR3RT2SLu5zTz2E0a6vL68p2ma_eEz-dDYNuGXp3pKfl9d_lrdFOv769vVcl04UXNZbDgXzlWKS68sWKhL4VjTgFDayUbraoNWOQEl06XkwqKVytfohS8dMG_FKflx1N3a1owxdDYezGCDuVmuzWOPCV1qyas9ZPbsyI5xeJgxTaYLyWHb2h6zScMrVQOw_K6Mfv8P3Q1z7LOTTNVc11qAfF3u8j9SxOblAmDmMSWTUzL_UsrstyfFedOhfyGfY8nAxRH4E1o8vK1kbu9WR8m_vZCanA</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Auvray Kuentz, Marie</creator><creator>Hautefeuille, Vincent</creator><creator>Mestier, Louis</creator><creator>Coutzac, Clélia</creator><creator>Lecomte, Thierry</creator><creator>Nardon, Victor</creator><creator>Artru, Pascal</creator><creator>Turpin, Anthony</creator><creator>Drouillard, Antoine</creator><creator>Malka, David</creator><creator>Tran‐Minh, My‐Linh</creator><creator>Trouilloud, Isabelle</creator><creator>Lièvre, Astrid</creator><creator>Williet, Nicolas</creator><creator>Pernot, Simon</creator><creator>Touchefeu, Yann</creator><creator>Taieb, Julien</creator><creator>Hammel, Pascal</creator><creator>Zaanan, Aziz</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-1258-861X</orcidid><orcidid>https://orcid.org/0000-0002-7296-5464</orcidid><orcidid>https://orcid.org/0000-0001-8372-5653</orcidid><orcidid>https://orcid.org/0000-0001-5093-0212</orcidid><orcidid>https://orcid.org/0000-0002-7948-1331</orcidid></search><sort><creationdate>20230501</creationdate><title>Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study</title><author>Auvray Kuentz, Marie ; Hautefeuille, Vincent ; Mestier, Louis ; Coutzac, Clélia ; Lecomte, Thierry ; Nardon, Victor ; Artru, Pascal ; Turpin, Anthony ; Drouillard, Antoine ; Malka, David ; Tran‐Minh, My‐Linh ; Trouilloud, Isabelle ; Lièvre, Astrid ; Williet, Nicolas ; Pernot, Simon ; Touchefeu, Yann ; Taieb, Julien ; Hammel, Pascal ; Zaanan, Aziz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3824-b223cc7524d5a1a1863c0ff1359c4f997bea5c316096423aea45d8ed3d6c10da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Adenosquamous</topic><topic>adenosquamous carcinoma</topic><topic>advanced disease</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer</topic><topic>Carcinoma, Adenosquamous - chemically induced</topic><topic>Carcinoma, Adenosquamous - drug therapy</topic><topic>Chemotherapy</topic><topic>Deoxycytidine</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Leucovorin - therapeutic use</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Malignancy</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Paclitaxel</topic><topic>Paclitaxel - therapeutic use</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic carcinoma</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Squamous cell carcinoma</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Auvray Kuentz, Marie</creatorcontrib><creatorcontrib>Hautefeuille, Vincent</creatorcontrib><creatorcontrib>Mestier, Louis</creatorcontrib><creatorcontrib>Coutzac, Clélia</creatorcontrib><creatorcontrib>Lecomte, Thierry</creatorcontrib><creatorcontrib>Nardon, Victor</creatorcontrib><creatorcontrib>Artru, Pascal</creatorcontrib><creatorcontrib>Turpin, Anthony</creatorcontrib><creatorcontrib>Drouillard, Antoine</creatorcontrib><creatorcontrib>Malka, David</creatorcontrib><creatorcontrib>Tran‐Minh, My‐Linh</creatorcontrib><creatorcontrib>Trouilloud, Isabelle</creatorcontrib><creatorcontrib>Lièvre, Astrid</creatorcontrib><creatorcontrib>Williet, Nicolas</creatorcontrib><creatorcontrib>Pernot, Simon</creatorcontrib><creatorcontrib>Touchefeu, Yann</creatorcontrib><creatorcontrib>Taieb, Julien</creatorcontrib><creatorcontrib>Hammel, Pascal</creatorcontrib><creatorcontrib>Zaanan, Aziz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Auvray Kuentz, Marie</au><au>Hautefeuille, Vincent</au><au>Mestier, Louis</au><au>Coutzac, Clélia</au><au>Lecomte, Thierry</au><au>Nardon, Victor</au><au>Artru, Pascal</au><au>Turpin, Anthony</au><au>Drouillard, Antoine</au><au>Malka, David</au><au>Tran‐Minh, My‐Linh</au><au>Trouilloud, Isabelle</au><au>Lièvre, Astrid</au><au>Williet, Nicolas</au><au>Pernot, Simon</au><au>Touchefeu, Yann</au><au>Taieb, Julien</au><au>Hammel, Pascal</au><au>Zaanan, Aziz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>152</volume><issue>9</issue><spage>1894</spage><epage>1902</epage><pages>1894-1902</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression‐free survival (PFS) were evaluated by Kaplan‐Meier method. Ninety‐four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first‐line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine‐nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P = .67) or OS (P = .5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P = .002), PFS (median, 7.8 vs 4.7 months, P = .02) and OS (median, 12.7 vs 9.2 months, P = .35). This large study evaluating first‐line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
What's new?
Pancreatic adenosquamous carcinoma (PASC) is a rare pancreatic cancer subtype of uncertain histological origin. Owing to its scarcity, little is known about the efficacy of chemotherapy for PASC, particularly for advanced disease. Here, investigation of modern chemotherapy regimens in a large multicenter cohort consisting of patients with advanced PASC suggests that more recent regimens based on 5‐fluorouracil, particularly FOLFIRINOX (FX), as well as regimens based on gemcitabine, namely gemcitabine‐nab paclitaxel (GN), are more effective for advanced PASC compared to more conventional regimens. Notably, overall response rates and survival rates were improved in advanced PASC patients on FX and GN regimens.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>36562310</pmid><doi>10.1002/ijc.34414</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1258-861X</orcidid><orcidid>https://orcid.org/0000-0002-7296-5464</orcidid><orcidid>https://orcid.org/0000-0001-8372-5653</orcidid><orcidid>https://orcid.org/0000-0001-5093-0212</orcidid><orcidid>https://orcid.org/0000-0002-7948-1331</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2023-05, Vol.152 (9), p.1894-1902 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03969427v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenocarcinoma Adenosquamous adenosquamous carcinoma advanced disease Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Carcinoma, Adenosquamous - chemically induced Carcinoma, Adenosquamous - drug therapy Chemotherapy Deoxycytidine Fluorouracil - therapeutic use Gemcitabine Humans Leucovorin - therapeutic use Life Sciences Male Malignancy Medical research Metastases Paclitaxel Paclitaxel - therapeutic use Pancreas Pancreatic cancer Pancreatic carcinoma Pancreatic Neoplasms Pancreatic Neoplasms - pathology Prospective Studies Retrospective Studies Squamous cell carcinoma Survival |
| title | Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T20%3A04%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy%20in%20advanced%20pancreatic%20adenosquamous%20carcinoma:%20A%20retrospective%20multicenter%20AGEO%20study&rft.jtitle=International%20journal%20of%20cancer&rft.au=Auvray%20Kuentz,%20Marie&rft.date=2023-05-01&rft.volume=152&rft.issue=9&rft.spage=1894&rft.epage=1902&rft.pages=1894-1902&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.34414&rft_dat=%3Cproquest_hal_p%3E2782989314%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2782989314&rft_id=info:pmid/36562310&rfr_iscdi=true |